Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lin CH, Chang CC, Wang CC, Chang MS, Yang LL
------>authors3_c=None
------>paper_class1=1
------>Impact_Factor=None
------>paper_class3=2
------>paper_class2=1
------>vol=54
------>confirm_bywho=hsu0320
------>insert_bywho=crystal
------>Jurnal_Rank=None
------>authors4_c=None
------>comm_author=
------>patent_EDate=None
------>authors5_c=None
------>publish_day=None
------>paper_class2Letter=None
------>page2=1278
------>medlineContent=
------>unit=G0200
------>insert_date=20020710
------>iam=3
------>update_date=
------>author=???
------>change_event=5
------>ISSN=None
------>authors_c=None
------>score=500
------>journal_name=J. Pharmacy and Pharmacology
------>paper_name=Byakangelicol, isolated from Angelica dahurica, inhibits both the activity and induction of cyclooxygenase-2 in human pulmonary epithelial cells
------>confirm_date=20030510
------>tch_id=088003
------>pmid=12356282
------>page1=1271
------>fullAbstract=We examined the inhibitory mechanism of byakangelicol, isolated from Angelica dahurica, on interleukin-1beta (IL-1beta)-induced cyclooxygenase-2 (COX-2) expression and prostaglandin E2 (PGE2) release in human pulmonary epithelial cell line (A549). Byakangelicol (10-50 microM) concentration-dependently attenuated IL-1beta-induced COX-2 expression and PGE2 release. The selective COX-2 inhibitor, NS-398 (0.01-1 microM), and byakangelicol (10-50 microM) both concentration-dependently inhibited the activity of the COX-2 enzyme. Byakangelicol, at a concentration up to 200 microM, did not affect the activity and expression of COX-1 enzyme. IL-1beta-induced p44/42 mitogen-activated protein kinase (MAPK) activation was inhibited by the MAPK/extracellular signal-regulated protein kinase (MEK) inhibitor, PD 98059 (30 microM), while byakangelicol (50 microM) had no effect. Treatment of cells with byakangelicol (50 microM) or pyrrolidine dithiocarbamate (PDTC; 50 microM) partially inhibited IL-1beta-induced degradation of IkappaB-alpha in the cytosol, translocation of p65 NF-kappaB from the cytosol to the nucleus and the NF-kappaB-specific DNA-protein complex formation. Taken together, we have demonstrated that byakangelicol inhibits IL-1beta-induced PGE2 release in A549 cells; this inhibition may be mediated by suppression of COX-2 expression and the activity of COX-2 enzyme. The inhibitory mechanism of byakangelicol on IL-1beta-induced COX-2 expression may be, at least in part, through suppression of NF-kappaB activity. Therefore, byakangelicol may have therapeutic potential as an anti-inflammatory drug on airway inflammation.
------>tmu_sno=None
------>sno=5694
------>authors2=None
------>authors3=None
------>authors4=None
------>authors5=None
------>authors6=None
------>authors6_c=None
------>authors=Lin CH, Chang CC, Wang CC, Chang MS, Yang LL
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=None
------>publish_area=None
------>updateTitle=Byakangelicol, isolated from Angelica dahurica, inhibits both the activity and induction of cyclooxygenase-2 in human pulmonary epithelial cells.
------>language=2
------>check_flag=
------>submit_date=
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=
------>publish_year=2002
------>submit_flag=
------>publish_month=None
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z